PDS Biotech Corporation, a clinical-stage immunotherapy company developing novel infectious disease vaccines and cancer therapies on the basis of its proprietary InfectimuneTM and Versamune® T-cell activating technologies.
Because there are so many different strains of flu, a new seasonal flu vaccine is generally created to defend against the strains that are projected to be the most common during the upcoming flu season. As a result, the existing vaccinations’ protective effectiveness varies greatly from one season to the next. PDS Biotech is working on a new generation of flu vaccinations that might give long-lasting and wide protection against numerous flu strains.
In the studies, PDS0202 was found to stimulate the generation of broadly neutralising influenza-specific antibodies, flu-specific CD8 (killing) and CD4 (helper) T-cells, and long-lasting memory T-cells. This well-understood and powerful immune response to COBRA antigens implies a high likelihood of widespread and long-term protection against a variety of influenza strains.
Be First to Comment